Monopteros Therapeutics is a clinical-stage biotechnology company developing a first-in-class inhibitor of MALT1 protease. The company’s first asset MPT-0118, is conducting a phase 1 clinical trial to investigate reprogramming regulatory T cells in solid tumors.

Biotechnology

Monopteros

Monopteros' headquarters in Boston, MA, United States

Peter Keller

Norma Kim Ascroft

Jon Lawson

Arthur DeCillis

Debasish Roychowdhury

Keith Flaherty

Shyam Masrani

John Baldoni

Ulrich von Andrian

Thorsten Mempel

Daniel Krappmann

Arlene Sharpe

Francesco De Rubertis

Description

People (3)

Peter Keller

Norma Kim Ascroft

Yun Gao

Jobs